US20040102416A1 - Antiallergic composition - Google Patents
Antiallergic composition Download PDFInfo
- Publication number
- US20040102416A1 US20040102416A1 US10/702,607 US70260703A US2004102416A1 US 20040102416 A1 US20040102416 A1 US 20040102416A1 US 70260703 A US70260703 A US 70260703A US 2004102416 A1 US2004102416 A1 US 2004102416A1
- Authority
- US
- United States
- Prior art keywords
- stachyose
- atopic dermatitis
- dermatitis
- group
- antiallergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 17
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 39
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 39
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 21
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 11
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 230000007815 allergy Effects 0.000 claims description 11
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 230000003111 delayed effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 201000004624 Dermatitis Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 5
- 235000013681 dietary sucrose Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000019300 CLIPPERS Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000016374 Perilla frutescens var crispa Nutrition 0.000 description 1
- 235000015640 Perilla frutescens var frutescens Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an antiallergic composition, particularly to an antiallergic composition usable for daily intake for preventing onset of atopic dermatitis, and medicines, beverages and foods using the composition.
- Atopic dermatitis occurs as dry lichen like eczema, and is an intractable disease accompanying severe itch. While little is known about the mechanism of the onset of eczema of the atopic dermatitis, it has been made clear that the disease is related to allergic reactions type I and type IV.
- a type I allergy is an immediate allergy mainly related to IgE antibodies, wherein chemical transmitters such as histamine and leukotriene, and enzymes are released upon reaction of allergenic substances (allergens) with IgE on mast cells and basophils to cause inflammatory reactions on the skin.
- type I allergies are considered not to be directly related to lesions of eczema caused by the atopic dermatitis.
- a type IV allergy is called as a delayed allergy or cell mediated allergy that causes an inflammatory reaction related to lymphocytes, and the onset of the disease takes 24 to 72 hours after sensitization.
- stachyose has an antiallergic action, particularly an action for suppressing atopic dermatitis, and have completed the present invention.
- the present invention provides an antiallergic composition comprising stachyose as an effective ingredient.
- Stachyose is a tetrasaccharide contained, for example, in soy beans. Stachyose is a hardly digestible oligosaccharide, and has been known as a factor for activating Lactobacillus bifidus known to have an intestinal function controlling drug among intestinal bacteria, and for accelerating absorption of calcium through the digestive intestine.
- the action for suppressing atopic dermatitis as disclosed in the present invention has not been known in the art.
- a standard of the desirable amount of intake is 1 to 15 g per day.
- a content of less than 1 g is not so effective, while a content of more than 20 g may induce temporary diarrhea, although it depends on physical conditions.
- FIG. 1 is a graph showing the scores of dermatitis in the stachyose administration group and control group
- FIG. 2 is a graph showing the scores of dermatitis in the saccharose administration group and control group
- FIG. 3 is photographs of appearances of test mice
- FIG. 4 is a graph showing the IgE levels in the stachyose administration group, and saccharose administration group and control group.
- FIG. 5 is a graph showing scores of dermatitis in the stachyose administration group and conrol group in the conventional NC/Nga mice.
- NC/Nga Tnd Crj male mice at six weeks of age were habituated for two weeks.
- the animals decided as healthy were used for the experiments after an observation of general conditions and body weight measurement.
- the mice were divided into three groups so that the body weight was averaged
- One group was composed of nine mice.
- a purified livesock feed (AIN93G produced by Oriental Yeast Co.) was used as a basic feed.
- mice in Group 1 (a control group) was fed with the purified feed, while the mice in Groups 2 and 3 were fed with a feed prepared by adding the test samples as shown in Table 1 in the basic feed.
- Table 1 TABLE 1 Group 1 AIN93G feed Group 2 AIN93G feed + stachyose 0.5%
- Stachyose used in this test was purified to a purity of 98% by ion exchange chromatography after extracting from soybeans with 70% ethanol. Saccharose used in this test was purchased from Wako Junyaku Kabushiki Kaisha.
- mice at eight weeks of age were used for sensitization as follows.
- the abdomen of the mouse anesthetized with ether was clipped with a pair of hair clippers and a solution of 2,4,6-trinitrochlorobenzene (named as picryl chloride (PiCl) hereinafter) for sensitization was applied on the abdomen after clipping and on the footpad in a proportion of 150 ⁇ L/one animal.
- Induction was started four days after sensitization, and repeated once a week for five weeks.
- the back of the mouse anesthetized with ether was clipped with a pair of hair clippers, and the PiCl solution (150 ⁇ L/one animal) was applied on the clipped back and right and left ears (at the outer and inner sides of each ear).
- the hair was clipped after the second induction depending on the growth of the hair.
- the symptoms of the atopic dermatitis were observed as follows. The skin condition was observed twice a week starting from a day before the first induction, and the following items were evaluated based on the criteria of clinical syndromes of the human atopic dermatitis. Each mouse was photographed on the day of autopsy.
- the serum total IgE concentration was measured as follows.
- the blood was extracted on day four before administration, and on 43rd day after administration (the day for starting administration is counted as the first day).
- the blood (200 ⁇ L) is sampled from the orbital plexus venosus using a heparinated capillary.
- the blood sampled was placed in a tube, centrifuged (at about 4° C. and 1660 g for 15 minutes), and IgE in the supernatant was used for the serum total IgE measurement by an enzyme-linked immunosorbent assay (EIA).
- EIA enzyme-linked immunosorbent assay
- FIGS. 1 and 2 The data of the score of dermatitis are shown in FIGS. 1 and 2. As shown in FIG. 1, progress of the atopic dermatitis was evidently bred in the stachyose administration group (Group 2). No effects were observed in the saccharose administration group (Group 3) as shown in FIG. 2. The photograph of the appearance of a representative mouse in each group is shown in FIG. 3. An evident difference of the appearance of the skin was observed in the mouse in the stachyose administration group as compared with the mouse in the control group (Group 1).
- stachyose While the expression mechanism of the anti-atopic dermatitis action of stachyose has not been made clear yet, it may be conjectured that stachyose probably acts on intestinal microorganisms to improve immunity of the digestive intestine. Otherwise, stachyose may directly act on the cells related to immunity of the digestive intestine. While the atopic dermatitis is considered to be related to the immediate allergy and delayed allergy (type IV), it was made clear from the results of the present invention that stachyose has a function against the delayed allergy since stachyose does not influence the level of IgE.
- raffinose as a minute component of the soy bean oligosaccharide has an ant-atopic dermatitis action (Japanese Patent Application Laid-open No. Hei 11-255656), raffinose has an action for suppressing production of IgE (Japanese Patent Application Laid-open No. 2001-288093). Accordingly, the action of stachyose shown in the present invention is evidently different from the action of raffinose.
- mice at four weeks of age were habituated for one week The mice were divided into two groups so that the body weight was averaged. One group was composed of six mice. All the mice were freely fed on the purified livestock feed (AIN93G) before grouping, and the stachyose administration group was fed on a feed supplemented with 1% stacyose after grouping. The sldn conditions were observed and evaluated once per two weeks from the day of start of grouping. The evaluation method was the same as in performance evaluation method 1.
- stachyose used in the present invention are not particularly rested, and any one of natural stachyose, chemically synthesized stachyose and enzymatically synthesized stachyose may be used.
- stachyose originating from soy beans is economically advantageous. Since stachyose is a principal ingredient of the soybean oligosaccharide, the oligosaccharide may be direly used as the stachyose source, or it may be used after purification by ion exchange chromatography.
- Beverage supplemented with soy bean oligosaccharide and stachyose was produced with sterilization after mixing.
- composition blended with stachyose of the present invention exhibits an atopic dermatitis suppressing effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention provides a safe and excellent antiallergic composition, and more particularly a preventive and therapeutic composition for atopic dermatitis, including an antiallergic composition blended with stachyose as an effective ingredient, and a medicine, food and beverage containing the composition.
Description
- 1. Field of the Invention
- The present invention relates to an antiallergic composition, particularly to an antiallergic composition usable for daily intake for preventing onset of atopic dermatitis, and medicines, beverages and foods using the composition.
- 2. Description of the Related Art
- Allergic diseases such as atopic dermatitis have caused severe problems in recent years. Atopic dermatitis occurs as dry lichen like eczema, and is an intractable disease accompanying severe itch. While little is known about the mechanism of the onset of eczema of the atopic dermatitis, it has been made clear that the disease is related to allergic reactions type I and type IV. A type I allergy is an immediate allergy mainly related to IgE antibodies, wherein chemical transmitters such as histamine and leukotriene, and enzymes are released upon reaction of allergenic substances (allergens) with IgE on mast cells and basophils to cause inflammatory reactions on the skin. However, type I allergies are considered not to be directly related to lesions of eczema caused by the atopic dermatitis. A type IV allergy is called as a delayed allergy or cell mediated allergy that causes an inflammatory reaction related to lymphocytes, and the onset of the disease takes 24 to 72 hours after sensitization.
- Many protective and therapeutic actions have been attempted for preventing atopic dermatitis. Representative examples thereof include (1) an external medication using external medicines such as adrenocortical hormones, and (2) administration of medicines that suppress immediate reactions such as antihistamine agents. However, the effect of medication is not always sufficient depending on the physical conditions of patents, and the medication has a risk of rebound.
- In addition, people with allergic physical conditions have been increasing every year. In extreme examples, the allergic symptom is so sever that daily life of the patient is hindered, which leads to social problems. Under these situations, there is an urgency to develop safe and excellent antiallergic medicines to solve the above mentioned problems, particularly prophylactics and medicaments of the atopic dermatitis.
- It is an object of the present invention to provide a safe and excellent antiallergic composition, particularly preventive and therapeutic compositions of the atopic dermatitis by solving the problems above on allergic diseases.
- The inventors have found, through intensive studies for attaining the objects above, that stachyose has an antiallergic action, particularly an action for suppressing atopic dermatitis, and have completed the present invention.
- The present invention provides an antiallergic composition comprising stachyose as an effective ingredient.
- Stachyose is a tetrasaccharide contained, for example, in soy beans. Stachyose is a hardly digestible oligosaccharide, and has been known as a factor for activatingLactobacillus bifidus known to have an intestinal function controlling drug among intestinal bacteria, and for accelerating absorption of calcium through the digestive intestine. However, the action for suppressing atopic dermatitis as disclosed in the present invention has not been known in the art.
- While the content of stachyose in the antiallergic composition is not particularly restricted, a standard of the desirable amount of intake is 1 to 15 g per day. A content of less than 1 g is not so effective, while a content of more than 20 g may induce temporary diarrhea, although it depends on physical conditions.
- FIG. 1 is a graph showing the scores of dermatitis in the stachyose administration group and control group;
- FIG. 2 is a graph showing the scores of dermatitis in the saccharose administration group and control group;
- FIG. 3 is photographs of appearances of test mice;
- FIG. 4 is a graph showing the IgE levels in the stachyose administration group, and saccharose administration group and control group; and
- FIG. 5 is a graph showing scores of dermatitis in the stachyose administration group and conrol group in the conventional NC/Nga mice.
- The performance of stachyose mixed in livestock feeds was evaluated against the dermatitis induced by repeated application of hapten on an NC/Nga mouse frequently used as an atopic dermatitis model animal (M. Okada et al., Oyo Yakuri/Pharmcometrics, vol. 59, 135-139 (2000)).
- NC/Nga Tnd Crj male mice at six weeks of age (purchased from Nihon Charles River) were habituated for two weeks. The animals decided as healthy were used for the experiments after an observation of general conditions and body weight measurement. The mice were divided into three groups so that the body weight was averaged One group was composed of nine mice. A purified livesock feed (AIN93G produced by Oriental Yeast Co.) was used as a basic feed.
- The mice in Group 1 (a control group) was fed with the purified feed, while the mice in
Groups TABLE 1 Group 1AIN93G feed Group 2 AIN93G feed + stachyose 0.5% Group 3AIN93G feed + saccharose 0.5% - Stachyose used in this test was purified to a purity of 98% by ion exchange chromatography after extracting from soybeans with 70% ethanol. Saccharose used in this test was purchased from Wako Junyaku Kabushiki Kaisha.
- The mice at eight weeks of age were used for sensitization as follows. The abdomen of the mouse anesthetized with ether was clipped with a pair of hair clippers and a solution of 2,4,6-trinitrochlorobenzene (named as picryl chloride (PiCl) hereinafter) for sensitization was applied on the abdomen after clipping and on the footpad in a proportion of 150 μL/one animal. Induction was started four days after sensitization, and repeated once a week for five weeks. In the induction period, the back of the mouse anesthetized with ether was clipped with a pair of hair clippers, and the PiCl solution (150 μL/one animal) was applied on the clipped back and right and left ears (at the outer and inner sides of each ear). The hair was clipped after the second induction depending on the growth of the hair.
- The symptoms of the atopic dermatitis were observed as follows. The skin condition was observed twice a week starting from a day before the first induction, and the following items were evaluated based on the criteria of clinical syndromes of the human atopic dermatitis. Each mouse was photographed on the day of autopsy.
- (1) Observed items
- a. pruritus/itching
- b. erythema/hemorrhage
- c. edema
- e. excoriation/erosion
- f. scaring/dryness
- (2) Evaluation point
- 0 no syndrome
- 1 mild syndrome
- 2 intermediate syndrome
- 4 severe syndrome
- The serum total IgE concentration was measured as follows. The blood was extracted on day four before administration, and on 43rd day after administration (the day for starting administration is counted as the first day). The blood (200 μL) is sampled from the orbital plexus venosus using a heparinated capillary. The blood sampled was placed in a tube, centrifuged (at about 4° C. and 1660 g for 15 minutes), and IgE in the supernatant was used for the serum total IgE measurement by an enzyme-linked immunosorbent assay (EIA).
- The score of dermatitis, serum total IgE concentration, and the average body weight and standard deviation thereof were calculated. The significant difference was evaluated by the student's test. A significance level of 5% was evaluated as significant, and the results of the Students t-test were expressed by dividing into a level of less than 5% (P<0.05) and less than 1% (P<0.01).
- The data of the score of dermatitis are shown in FIGS. 1 and 2. As shown in FIG. 1, progress of the atopic dermatitis was evidently bred in the stachyose administration group (Group 2). No effects were observed in the saccharose administration group (Group 3) as shown in FIG. 2. The photograph of the appearance of a representative mouse in each group is shown in FIG. 3. An evident difference of the appearance of the skin was observed in the mouse in the stachyose administration group as compared with the mouse in the control group (Group 1).
- The levels of the serum total IgE as an immediate type (type I) allergy inducing substance are shown in FIG. 4. These levels were not different from the level in the control group.
- While the expression mechanism of the anti-atopic dermatitis action of stachyose has not been made clear yet, it may be conjectured that stachyose probably acts on intestinal microorganisms to improve immunity of the digestive intestine. Otherwise, stachyose may directly act on the cells related to immunity of the digestive intestine. While the atopic dermatitis is considered to be related to the immediate allergy and delayed allergy (type IV), it was made clear from the results of the present invention that stachyose has a function against the delayed allergy since stachyose does not influence the level of IgE. While it is known in the art that raffinose as a minute component of the soy bean oligosaccharide has an ant-atopic dermatitis action (Japanese Patent Application Laid-open No. Hei 11-255656), raffinose has an action for suppressing production of IgE (Japanese Patent Application Laid-open No. 2001-288093). Accordingly, the action of stachyose shown in the present invention is evidently different from the action of raffinose.
- The effect of stachyose on the dermatitis was investigated using conventional grade NC/Nga mice that spontaneously start the atopic dermatitis without applying any haptens (H. Matsuda et al., International Immunology, vol. 9. 461-466 (1997)).
- Conventional grade female NC/Nga mice at four weeks of age (purchased from Nihon SLC) were habituated for one week The mice were divided into two groups so that the body weight was averaged. One group was composed of six mice. All the mice were freely fed on the purified livestock feed (AIN93G) before grouping, and the stachyose administration group was fed on a feed supplemented with 1% stacyose after grouping. The sldn conditions were observed and evaluated once per two weeks from the day of start of grouping. The evaluation method was the same as in
performance evaluation method 1. - While the dermatitis was observed on the face of five of six mice in the control group on the week four after grouping, no onset of the dermatitis was observed in the stachyose administration group. While evident dermatitis was observed not only on the face but also on the ears in the
control group 6 to 8 weeks after grouping, no onset of dermatitis was observed at all in the stachyose administration group. The scores of dermatitis are shown in FIG. 5. The scores of dermatitis show that the effect of stachyose is evident - The origin and production method of stachyose used in the present invention are not particularly rested, and any one of natural stachyose, chemically synthesized stachyose and enzymatically synthesized stachyose may be used. However, stachyose originating from soy beans is economically advantageous. Since stachyose is a principal ingredient of the soybean oligosaccharide, the oligosaccharide may be direly used as the stachyose source, or it may be used after purification by ion exchange chromatography.
- While the present invention is described with reference to examples, the present invention is by no means restricted by the examples as set forth below.
-
[Ingredient of Capsule] Starting Material Blend (mg) per 1 Capsule (1) Stachyose 50 (2) DHA Oil 50 (3) Beefsteak Plant Oil 50 (4) Bee Wax 50 - These materials were capsulated using gelatin after mixing.
-
[Tablet] Starting Material Blend (mg) per 1 Capsule (1) Stachyose 100 (2) Lactose 100 (3) Cellulose Powder 50 (4) Reduced Maltose 30 (5) Processed Starch 10 (6) Calcium Carbonate 1 - These materials were formulated into tablets after mixing.
-
[Beverage] Starting Material Blend (g) per 1 Bottle (1) Soy Bean Oligosaccharide (Stachyose 50%) 2 (2) Sucrose 10 (3) Coffee Powder 5 (4) Cow Milk 183 - Beverage supplemented with soy bean oligosaccharide and stachyose was produced with sterilization after mixing.
- It is evident that the composition blended with stachyose of the present invention exhibits an atopic dermatitis suppressing effect.
Claims (5)
1. An antiallergic composition comprising stachyose as an effective ingredient.
2. The antiallergic composition according to claim 1 , wherein the stachyose is originated from soybeans.
3. The antiallergic composition according to any one of claims 1 and 2. wherein an antiallergic function is an action for suppressing atopic dermatitis.
4. The antiallergic composition according to any one of claims 1 to 3 , wherein the antiallergic function is an action for suppressing a delayed allergy.
5. A medicine, and beverage and food comprising the antiallergic composition according to any one of claims 1 to 4 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/187,913 US7166582B2 (en) | 2002-05-02 | 2005-07-25 | Antiallergic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002130875A JP4178829B2 (en) | 2002-05-02 | 2002-05-02 | Antiallergic composition |
JP2002-130875 | 2002-05-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/187,913 Division US7166582B2 (en) | 2002-05-02 | 2005-07-25 | Antiallergic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040102416A1 true US20040102416A1 (en) | 2004-05-27 |
Family
ID=29543763
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/702,607 Abandoned US20040102416A1 (en) | 2002-05-02 | 2003-11-07 | Antiallergic composition |
US11/187,913 Expired - Fee Related US7166582B2 (en) | 2002-05-02 | 2005-07-25 | Antiallergic composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/187,913 Expired - Fee Related US7166582B2 (en) | 2002-05-02 | 2005-07-25 | Antiallergic composition |
Country Status (2)
Country | Link |
---|---|
US (2) | US20040102416A1 (en) |
JP (1) | JP4178829B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1529532A1 (en) * | 2003-11-07 | 2005-05-11 | Kabushiki Kaisha Honen Corporation | Antiallergic composition comprising stachyose |
JP7274720B2 (en) * | 2018-09-26 | 2023-05-17 | 株式会社クラブコスメチックス | Estrogen receptor expression promoter and cell proliferation promoter |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994326A (en) * | 1998-03-10 | 1999-11-30 | Nippon Tensaiseito Kabushiki Kaisha | Anti-atopic dermatitis composition |
US20030157200A1 (en) * | 2000-07-07 | 2003-08-21 | Frederic Bonte | Use of oligosaccharides to stimulate beta-endorphin production |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62198694A (en) | 1986-02-27 | 1987-09-02 | Fuji Oil Co Ltd | Purification of oligosaccharide |
JPH0386825A (en) * | 1989-06-15 | 1991-04-11 | Tokyo Tanabe Co Ltd | Aerosol agent of pyrido(1,2-a)pyrimidine derivative |
JP2816726B2 (en) | 1989-11-10 | 1998-10-27 | カルピス株式会社 | Composition for improving intestinal environment |
IL119107A (en) | 1996-08-21 | 1999-05-09 | Chajuss Daniel | Modified soy molasses |
CN1130368C (en) | 1998-01-12 | 2003-12-10 | 济南三株药业有限公司 | Process for preparing stachyose and its products and application |
KR20010015628A (en) | 1998-07-27 | 2001-02-26 | 존 이. 앤더슨 | Topical compositions containing sialyl sugars and their derivatives |
FR2802414B1 (en) | 1999-12-20 | 2003-06-27 | G Pharm Lab | COMPOSITION, ESPECIALLY COSMETIC OR DERMATOLOGICAL, CONTAINING OLIGOSACCHARIDES, METHOD FOR THE PREPARATION THEREOF AND METHOD FOR THE COSMETIC TREATMENT |
JP4024454B2 (en) | 2000-03-31 | 2007-12-19 | 日本甜菜製糖株式会社 | IgE antibody production reducing agent and allergic constitution improving agent |
JP3451244B2 (en) | 2000-08-21 | 2003-09-29 | 株式会社ファンケル | Food composition |
-
2002
- 2002-05-02 JP JP2002130875A patent/JP4178829B2/en not_active Expired - Fee Related
-
2003
- 2003-11-07 US US10/702,607 patent/US20040102416A1/en not_active Abandoned
-
2005
- 2005-07-25 US US11/187,913 patent/US7166582B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994326A (en) * | 1998-03-10 | 1999-11-30 | Nippon Tensaiseito Kabushiki Kaisha | Anti-atopic dermatitis composition |
US20030157200A1 (en) * | 2000-07-07 | 2003-08-21 | Frederic Bonte | Use of oligosaccharides to stimulate beta-endorphin production |
Also Published As
Publication number | Publication date |
---|---|
JP4178829B2 (en) | 2008-11-12 |
JP2003321372A (en) | 2003-11-11 |
US20050256084A1 (en) | 2005-11-17 |
US7166582B2 (en) | 2007-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pavel et al. | Biological activities of royal jelly-review | |
EP0103836B1 (en) | Dietary and pharmaceutical compositions comprising methylsulfonylmethane | |
RU2469719C2 (en) | METHOD OF TREATING ALLERGY, METHOD OF TREATING ASTHMA, METHOD OF REDUCING RISK OF DEVELOPING INFECTION, AND METHOD OF TREATING CONDITION CHARACTERISED BY CYTOKINE TYPE 1 AND 2 CONTENT IMBALANCE BY β-HYDROXY-β-METHYLBUTYRATE | |
TWI494114B (en) | Use of lgg for treating, preventing or reducing systemic inflammation | |
WO2021197492A1 (en) | Breast milk oligosaccharides for improving resistance of organism against staphylococcus aureus infection | |
JP4741801B2 (en) | Composition for preventing or treating hay fever, allergic rhinitis, atopic dermatitis, asthma or urticaria | |
KR20070054739A (en) | Total enteral nutritious composition | |
US4559329A (en) | Dietary and pharmaceutical uses of methyl-sulfonylmethane and compositions comprising it | |
EP2397039A1 (en) | Compositions for delaying progression of diabetes using Salacia oblonga extract | |
CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
CN112823667A (en) | Application of composition in preventing or relieving infantile intestinal colic | |
US10758562B2 (en) | Gel formulation for the prevention and treatment of gastrointestinal distress in horses and other species | |
US11439676B2 (en) | Method for prevention or treating gastrointestinal distress in humans using mastic gum compositions | |
EP3027056A2 (en) | Immunity micronutrition | |
EP3462906A1 (en) | Method and supplement for the prevention and treatment of gastrointestinal distress in horses and other species | |
CN110099691A (en) | Maca composition and application method | |
US20200397861A1 (en) | Process of preparation of glycan compositions & uses thereof | |
US7229646B2 (en) | Methods and compositions for modulating immune response and for the treatment of inflammatory disease | |
US7166582B2 (en) | Antiallergic composition | |
EP1529532A1 (en) | Antiallergic composition comprising stachyose | |
JP2008231094A (en) | Antiallergic agent | |
WO2002038146A1 (en) | Mucosal immunomodulator and use thereof | |
JP2023154540A (en) | Composition for preventing or improving age-related hearing loss | |
JP4024454B2 (en) | IgE antibody production reducing agent and allergic constitution improving agent | |
KR20090035682A (en) | Immunomodulating agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KABUSHIKI KAISHA HONEN CORPORATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SATO, TOSHIRO;KAMO, SHUICHI;OHTANI, YUTAKA;AND OTHERS;REEL/FRAME:014678/0811 Effective date: 20031107 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |